China's GenScript Biotech H1 revenue rises on AI drug discovery

Genscript Biotech

18/08/2026 15:13

Overview
China biotech service provider's H1 2026 revenue rose 27.3% yr/yr, driven by AI drug discovery
Adjusted net profit for H1 2026 surged 203.3% yr/yr
Gene-to-Protein platform generated 66% of segment revenue and remained primary growth engine

Outlook
GenScript expects higher demand and increased utilization to support continued revenue growth and profitability
Ongoing investment in technology and automation to expand support for complex AI-enabled drug discovery
ProBio's growing order base and Bestzyme's AI-enabled capabilities seen as platforms for long-term growth

Result Drivers
AI-ENABLED DRUG DISCOVERY - Business doubled year over year, driven by demand from AI-focused biotech and pharma companies
GENE-TO-PROTEIN PLATFORM - Accounted for 66% of segment revenue and remained primary growth engine
OPERATING EFFICIENCY - Improved operating efficiency contributed to higher profitability

Company press release: ID:nPnbDyy3Xa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
$319 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Genscript Biotech Corp is HK$24.62, about 12.9% below its August 18 closing price of HK$28.26
The stock recently traded at 51 times the next 12-month earnings vs. a P/E of 40 three months ago

Reuters Recommended Reads
Aug 17 - China's Sichuan Kelun-Biotech swings to profit in H1 on new product approvals
Aug 17 - Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech
Aug 17 - Vaccine maker Sinovac H1 revenue rises on overseas growth, approvals

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)